Literature DB >> 23667874

Comparative evaluation of the efficiency of prostatotropic agents of natural origin in experimental benign prostatic hyperplasia.

T G Borovskaya1, T I Fomina, L A Ermolaeva, A V Vychuzhanina, A V Pakhomova, M E Poluektova, Yu A Shchemerova.   

Abstract

Comparative evaluation of the efficiency of prostatotropic agents was carried out in rat experiments. Serenoa repens plant preparation and polypeptides isolated from the cattle prostate were used for the treatment of benign hyperplasia. Drugs in parallel with sulpiride similarly led to shrinkage of the acinar epithelial area and to emergence of a trend to an increase of the stromal/epithelial proportion, more so after Serenoa repens treatment.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23667874     DOI： 10.1007/s10517-013-2081-9

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  2 in total

1.  Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Authors:  Ekaterina A Lesovaya; Kirill I Kirsanov; Elena E Antoshina; Lubov S Trukhanova; Tatiana G Gorkova; Elena V Shipaeva; Ramiz M Salimov; Gennady A Belitsky; Mikhail V Blagosklonny; Marianna G Yakubovskaya; Olga B Chernova
Journal:  Oncotarget       Date:  2015

Review 2.  Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms.

Authors:  Celeste De Monte; Simone Carradori; Arianna Granese; Giovanni Battista Di Pierro; Costantino Leonardo; Cosimo De Nunzio
Journal:  BMC Urol       Date:  2014-08-11       Impact factor: 2.264
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.